These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 16855074)
1. FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects. Schmouder R; Serra D; Wang Y; Kovarik JM; DiMarco J; Hunt TL; Bastien MC J Clin Pharmacol; 2006 Aug; 46(8):895-904. PubMed ID: 16855074 [TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study. Kahan BD; Karlix JL; Ferguson RM; Leichtman AB; Mulgaonkar S; Gonwa TA; Skerjanec A; Schmouder RL; Chodoff L Transplantation; 2003 Oct; 76(7):1079-84. PubMed ID: 14557756 [TBL] [Abstract][Full Text] [Related]
3. FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction. Kovarik JM; Schmouder RL; Barilla D; Büche M; Rouilly M; Berthier S; Wang Y; Van Saders C; Mayer T; Gottlieb AB Ann Pharmacother; 2004; 38(7-8):1153-8. PubMed ID: 15138297 [TBL] [Abstract][Full Text] [Related]
4. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. Kovarik JM; Schmouder R; Barilla D; Riviere GJ; Wang Y; Hunt T J Clin Pharmacol; 2004 May; 44(5):532-7. PubMed ID: 15102874 [TBL] [Abstract][Full Text] [Related]
5. A mechanistic study to assess whether isoproterenol can reverse the negative chronotropic effect of fingolimod. Kovarik JM; Riviere GJ; Neddermann D; Maton S; Hunt TL; Schmouder RL J Clin Pharmacol; 2008 Mar; 48(3):303-10. PubMed ID: 18218783 [TBL] [Abstract][Full Text] [Related]
6. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study. Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264 [TBL] [Abstract][Full Text] [Related]
7. Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects. Kovarik JM; Schmouder R; Barilla D; Wang Y; Kraus G Br J Clin Pharmacol; 2004 May; 57(5):586-91. PubMed ID: 15089811 [TBL] [Abstract][Full Text] [Related]
8. Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects. Kovarik JM; Hartmann S; Bartlett M; Riviere GJ; Neddermann D; Wang Y; Port A; Schmouder RL Biopharm Drug Dispos; 2007 Mar; 28(2):97-104. PubMed ID: 17230596 [TBL] [Abstract][Full Text] [Related]
9. The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects. Kovarik JM; Lu M; Riviere GJ; Barbet I; Maton S; Goldwater DR; Schmouder RL Eur J Clin Pharmacol; 2008 May; 64(5):457-63. PubMed ID: 18196225 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose fingolimod (FTY720) in adolescents with stable renal transplants. Ettenger R; Schmouder R; Kovarik JM; Bastien MC; Hoyer PF Pediatr Transplant; 2011 Jun; 15(4):406-13. PubMed ID: 21585629 [TBL] [Abstract][Full Text] [Related]
11. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. O'Connor P; Comi G; Montalban X; Antel J; Radue EW; de Vera A; Pohlmann H; Kappos L; Neurology; 2009 Jan; 72(1):73-9. PubMed ID: 19122034 [TBL] [Abstract][Full Text] [Related]
12. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years. Kisicki JC; Fiske K; Lyne A Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196 [TBL] [Abstract][Full Text] [Related]
15. Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers. Schmouder R; Hariry S; David OJ Eur J Clin Pharmacol; 2012 Apr; 68(4):355-62. PubMed ID: 22071882 [TBL] [Abstract][Full Text] [Related]
16. Differential effects of single dose FTY720 on CD62L+ B-cells in stable renal allograft recipients. Böhler T; Schütz M; Budde K; Neumayer HH; Waiser J Int Immunopharmacol; 2007 Jan; 7(1):88-95. PubMed ID: 17161821 [TBL] [Abstract][Full Text] [Related]
17. The immunomodulator FTY720 is phosphorylated and released from platelets. Anada Y; Igarashi Y; Kihara A Eur J Pharmacol; 2007 Jul; 568(1-3):106-11. PubMed ID: 17553484 [TBL] [Abstract][Full Text] [Related]
18. Impact of long-term therapy with FTY720 or mycophenolate mofetil on cardiac conduction and rhythm in stable adult renal transplant patients. Oppenheimer F; Mulgaonkar S; Ferguson R; Grinyó J; Juarez F; Ostrowski M; Klinger M; Walker R; Torres A; Preiss R; Cremer M; Jardine A; Transplantation; 2007 Mar; 83(5):645-8. PubMed ID: 17353787 [TBL] [Abstract][Full Text] [Related]
19. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Mehling M; Brinkmann V; Antel J; Bar-Or A; Goebels N; Vedrine C; Kristofic C; Kuhle J; Lindberg RL; Kappos L Neurology; 2008 Oct; 71(16):1261-7. PubMed ID: 18852441 [TBL] [Abstract][Full Text] [Related]
20. Evidence that FTY720 induces rat thymocyte apoptosis. Isoyama N; Takai K; Tsuchida M; Matsumura M; Naito K Transpl Immunol; 2006 Apr; 15(4):265-71. PubMed ID: 16635748 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]